Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2018 - 2025)

Historic Long-Term Deferred Tax for Protalix BioTherapeutics (PLX) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Protalix BioTherapeutics' Long-Term Deferred Tax fell 619.75% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 619.75%. This contributed to the annual value of $2.9 million for FY2024, which is 763.26% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Long-Term Deferred Tax stood at $2.7 million, which was down 619.75% from $2.7 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Long-Term Deferred Tax's 5-year high stood at $3.3 million during Q2 2024, with a 5-year trough of $2.7 million in Q3 2025.
  • In the last 3 years, Protalix BioTherapeutics' Long-Term Deferred Tax had a median value of $3.0 million in 2023 and averaged $3.0 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Long-Term Deferred Tax surged by 539.94% in 2024 and then crashed by 1700.52% in 2025.
  • Protalix BioTherapeutics' Long-Term Deferred Tax (Quarter) stood at $3.1 million in 2023, then fell by 7.63% to $2.9 million in 2024, then decreased by 6.2% to $2.7 million in 2025.
  • Its Long-Term Deferred Tax was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.0 million in Q1 2025.